Scholars Central

Conference abstractPublished 27 Mar 2023

Confronting obesity via new orally administered naltrexone/bupropion 3D-printed tablet formulations

Authors: Marilena Vlachou

National and Kapodistrian University of Athens, Greece

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Obesity is a disease characterised by excess body fat and is related with increased mortality and morbidity with associated conditions, like diabetes, cardiovascular diseases and the development of certain types of cancers, including esophageal, colon, and breast cancers (Tec, 2016). The last few decades, the rates of both obesity and the associated diseases have been exponentially increased worldwide. The use of approved pharmacotherapy is suggested in obese or overweight adults with at least one bodyweight-related comorbidity (e.g. type 2 diabetes, hypertension or dyslipidaemia) (Greig and Keating, 2015). Currently, the obesity menace is mainly confronted by the administration of a commercially available naltrexone/bupropion tablet formulation (Mysimba®), the use of which is, though, not devoid of serious side effects and especially cardiovascular related. In view of this, new compounded naltrexone/bupropion sustained/controlled release bilayer and 3D-printed delivery systems have been developed in our laboratory, aiming at improving the properties of the known naltrexone/bupropion systems. The data we have obtained, regarding the in vitro oral dissolution profile of the new matrix tablets are significant and will be utilized in future in vivo studies. The new 3D-printed naltrexone/bupropion carriers were prepared by the fused deposition modeling (FDM) method, which is utilized in the fabrication of 3D objects by extruding molten materials layer by layer on a platform. Recently, the applicability of this approach has been broadened and covers the medical/pharmaceutical area, as well, as the FDM printing process is nowadays widely used to manufacture drug delivery systems (Mathew et al., 2020). The new 3D printed naltrexone/bupropion carriers, we have developed, will be sought to be evolved in the future to 4D systems, where “time” is incorporated into the conventional concept of 3D printing, thus providing the Pharma with new prospects. Recent Publications 1. Zampakola, A. Siamidi, N. Pippa, C. Demetzos, M. Vlachou. Chronobiotic Hormone Melatonin: Comparative in vitro Release Studies from Matrix Tablets and Liposomal Formulations Lett Drug Des Discov, 14(4), 476-480, (2017). DOI: 10.2174/157018 0813666161006162246 2. M. Vlachou, A. Siamidi, E. Diamantidi, A. Iliopoulou, I. Papanastasiou, V. Ioannidou, V. Kourbeli, A.-S. Foscolos, A. Vocat, S.T. Colec, V. Karalis, T. Kellici, T. Mavromoustakos. In vitro Controlled Release from Solid Pharmaceutical Formulations of two new Adamantane Aminoethers with Antitubercular Activity (I) Drug Res, 67(8), 447-450, (2017). DOI: 10.1055/s-0042- 121491 (2017) 3. M. Vlachou, A. Siamidi, D. Spaneas, D. Lentzos, P. Ladia, K. Anastasiou, I. Papanastasiou, A-S. Foscolos, M-O. Georgiadis, V. Karalis, T. Kellici, T. Mavromoustakos. In vitro Controlled Release of two new Tuberculocidal Adamantane Aminoethers from Solid Pharmaceutical Formulations (II). Drug Res, 67(11), 653-660, (2017). DOI: 10.1055/s-0043-114012

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Medicinal Chemistry.

All its articles

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalMedicinal Chemistry
  • SubjectChemistry
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Marilena Vlachou”